International Assets Investment Management LLC Increases Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

International Assets Investment Management LLC lifted its holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 4,141.2% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,998 shares of the medical device company’s stock after buying an additional 6,833 shares during the period. International Assets Investment Management LLC’s holdings in Tandem Diabetes Care were worth $297,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. GAMMA Investing LLC boosted its stake in shares of Tandem Diabetes Care by 11.2% in the 2nd quarter. GAMMA Investing LLC now owns 4,276 shares of the medical device company’s stock worth $172,000 after buying an additional 431 shares during the last quarter. MN Wealth Advisors LLC lifted its stake in Tandem Diabetes Care by 3.1% in the second quarter. MN Wealth Advisors LLC now owns 14,723 shares of the medical device company’s stock valued at $593,000 after purchasing an additional 440 shares during the last quarter. Signaturefd LLC lifted its stake in Tandem Diabetes Care by 29.2% in the second quarter. Signaturefd LLC now owns 2,307 shares of the medical device company’s stock valued at $93,000 after purchasing an additional 522 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Tandem Diabetes Care by 4.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,960 shares of the medical device company’s stock valued at $603,000 after purchasing an additional 592 shares during the last quarter. Finally, ORG Wealth Partners LLC purchased a new position in Tandem Diabetes Care in the third quarter valued at approximately $30,000.

Analyst Upgrades and Downgrades

Several research firms recently commented on TNDM. Barclays upped their price objective on Tandem Diabetes Care from $55.00 to $58.00 and gave the company an “overweight” rating in a research note on Monday, August 5th. Morgan Stanley reiterated an “equal weight” rating and issued a $45.00 price objective on shares of Tandem Diabetes Care in a research note on Monday, September 23rd. The Goldman Sachs Group began coverage on Tandem Diabetes Care in a research note on Friday, October 4th. They issued a “neutral” rating and a $46.00 price objective on the stock. Wells Fargo & Company upped their price objective on Tandem Diabetes Care from $50.00 to $55.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Finally, Canaccord Genuity Group started coverage on Tandem Diabetes Care in a research report on Thursday, August 8th. They set a “buy” rating and a $57.00 target price on the stock. Five investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $54.31.

Tandem Diabetes Care Trading Up 3.4 %

Tandem Diabetes Care stock opened at $34.24 on Thursday. The stock has a market cap of $2.24 billion, a P/E ratio of -16.38 and a beta of 1.36. Tandem Diabetes Care, Inc. has a fifty-two week low of $13.82 and a fifty-two week high of $53.69. The firm’s fifty day moving average price is $39.21 and its 200-day moving average price is $41.88. The company has a debt-to-equity ratio of 1.31, a quick ratio of 2.38 and a current ratio of 3.05.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.